About Immunocore：Founded in Oxfordshire with offices in Philadelphia, USA, Immunocore is a world-leading biotechnology company focused on the development of a new class of immunotherapeutic drugs, based on proprietary T Cell Receptor (TCR) technology. The Company is primarily focused in the area of immuno-oncology but the technology also has potential for other conditions including infections and autoimmune diseases. The scientific expertise at Immunocore spans the entire process of drug development, from the discovery and validation of suitable disease targets, through the design and engineering of immune-activating TCR-based drugs, to preclinical, clinical assessment, manufacturing and regulatory affairs.
Clinical and Pipeline
Immunocore’s lead program, IMCgp100, is currently undergoing a pivotal clinical study as a monotherapy for the treatment of patients with metastatic uveal melanomas. Combination studies with IMCgp100 and other immunotherapies, including a Phase I/II study with checkpoint inhibitors durvalumab and tremelimumab from MedImmune (AstraZeneca), for patients with metastatic cutaneous melanoma, are currently recruiting. In addition, IMCgp100 has been granted Orphan Drug Designation by the US Food and Drug Administration (FDA) for the treatment of uveal melanoma.